Advertisement

Topics

Allergan’s Vraylar Receives FDA Approval for Use in the Maintenance Treatment of Schizophrenia

16:53 EST 14 Nov 2017 | Speciality Pharma Journal

DUBLIN, Nov. 13, 2017 /PRNewswire/ — Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for VRAYLAR™ (cariprazine) for the maintenance treatment of adults with schizophrenia. VRAYLAR is also approved in the U.S. in adults for the acute treatment of schizophrenia and acute treatment of manic or mixed episodes …

Original Article: Allergan’s Vraylar Receives FDA Approval for Use in the Maintenance Treatment of Schizophrenia

NEXT ARTICLE

More From BioPortfolio on "Allergan’s Vraylar Receives FDA Approval for Use in the Maintenance Treatment of Schizophrenia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...